Grant Pickering - Nov 19, 2021 Form 4 Insider Report for Vaxcyte, Inc. (PCVX)

Role
Chief Executive Officer, Director
Signature
/s/ Ron Metzger, Attorney-in-Fact
Stock symbol
PCVX
Transactions as of
Nov 19, 2021
Transactions value $
-$324,860
Form type
4
Date filed
11/23/2021, 04:10 PM
Previous filing
Oct 22, 2021
Next filing
Dec 28, 2021

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction PCVX Common Stock Options Exercise $26.9K +15K +2.59% $1.79 595K Nov 19, 2021 Direct
transaction PCVX Common Stock Sale -$210K -9.11K -1.53% $23.09 586K Nov 19, 2021 Direct F1, F2
transaction PCVX Common Stock Sale -$141K -5.89K -1% $24.00 580K Nov 19, 2021 Direct F1, F3
holding PCVX Common Stock 356K Nov 19, 2021 By Children's Trusts

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction PCVX Stock Option (right to buy) Options Exercise $0 -15K -4.36% $0.00 329K Nov 19, 2021 Common Stock 15K $1.79 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.
F2 The price reported is a weighted-average price. The shares were sold at prices ranging from $22.58 to $23.54. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
F3 The price reported is a weighted-average price. The shares were sold at prices ranging from $23.60 to $24.51. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
F4 The shares subject to the option are fully vested and exercisable.